Remission of Follicular Non-Hodgkin's Lymphoma with Denileukin Diftitox (ONTAK ® ) After Progression During Rituximab, CHOP and Fludarabine Therapy

Abstract

Denileukin diftitox (ONTAK ® ) is indicated for the treatment of patients with cutaneous T cell lymphoma. Clinical experience with this drug in other lymphomas is limited. This case report concern a patient with stage IV follicular lymphoma who, relapsing after autologous transplant and having failed multiply systemic therapies, including retuximab and CHOP, achieved a prolonged remission with denileukin diftitox.

• Follicular Non-Hodgkin's Lymphoma
• Denileukin Diftitox
• Refractory
• Autologous Peripheral Blood Stem Cell Transplant